China Will Not Supply H1N1 Vaccine To Hong Kong; Island Scrambles For Additional Tenders
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Mainland Chinese vaccine makers, the first in the world to receive domestic approval for an H1N1 vaccine, are unlikely to seek overseas approval for their products. This means that even Hong Kong and Macau will not have access to those products
You may also be interested in...
Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas
SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma
Korea FDA Evaluating H1N1 Vaccine Applications from GSK and Three Korean Pharmas
SEOUL - Korea FDA said it is evaluating three applications for the A/H1N1 flu vaccine submitted by GlaxoSmithKline and Korean companies Green Cross, Boryung Pharmaceutical and Hanwha Pharma
Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age